To determine whether the pyridostatin/NU‐7441/paclitaxel combination specifically suppresses growth of BRCA‐deficient, but not BRCA‐proficient tumours, we established xenograft tumours using BRCA2+/+ and BRCA2−/− HCT116 human cells. This evidence concerns the gene BRCA2 and neoplasm.